慢性硬膜下血肿管理进展:超越钻孔引流
慢性硬膜下血肿在衰弱、合并痴呆等共病人群中死亡率高于年龄匹配对照,发病率随人口老龄化上升。钻孔引流长期是主要手术方式,2020年以来多项高质量临床试验优化了手术策略、提供了反对常规使用类固醇的强证据,并探索了脑膜中动脉栓塞等微创治疗。单一方案并不适合所有患者,按不良结局危险因素分层可能对最大化辅助治疗获益至关重要。
要点
- 钻孔引流仍是慢性硬膜下血肿手术主要方式,但治疗正扩展至手术之外。
- 高质量试验提供反对常规使用类固醇的强证据。
- 按不良结局危险因素分层有助于最大化脑膜中动脉栓塞等辅助治疗获益。
核心结论
- 慢性硬膜下血肿治疗正超越钻孔引流,脑膜中动脉栓塞等微创与辅助治疗及危险因素分层受到关注。
- 单一治疗方式不适合所有患者,未来需多学科协作以改善结局。
研究设计与样本
- 综述类,检索范围未在原文中具体报告。
主要发现
- 慢性硬膜下血肿患者衰弱及痴呆等共病增加,死亡率高于年龄匹配对照,发病率随人口老龄化上升。
- 2020年以来多项高质量临床试验帮助优化了手术策略。
- 这些试验提供了反对常规使用类固醇的强证据。
- 已研究脑膜中动脉栓塞的微创治疗。
- 按不良结局危险因素分层可能对最大化辅助治疗获益至关重要。
临床怎么用
- 临床应认识到单一治疗方式不适合所有慢性硬膜下血肿患者。
- 可考虑按不良结局危险因素分层以指导脑膜中动脉栓塞等辅助治疗。
- 应重视多学科协作以改善患者结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic subdural haematoma is associated with increased frailty, comorbidities including dementia, and a higher risk of mortality compared to age-matched controls, with incidence rising as populations age. Burr holes have long been considered the mainstay of surgical treatment for chronic subdural haematoma, but novel therapies are seeking to expand treatment beyond surgical burr hole drainage. Since 2020, several high-quality clinical trials have helped refine operative strategies, provided robust evidence against the routine use of steroids, and investigated minimally invasive treatment with middle meningeal artery embolisation. One treatment approach does not fit all patients, and stratification using risk factors for poor outcome might prove crucial in maximising benefit from adjuvant therapies such as middle meningeal artery embolisation. Results of further trials of middle meningeal artery embolisation and drug trials are awaited, and increased recognition of the need for multispecialist care should also help to improve outcomes for patients with chronic subdural haematoma in the future.
引用
- Edlmann E, Davies BM, Stubbs DJ, et al. Advances in chronic subdural haematoma management: beyond the burr hole. Lancet Neurol. 2026. PMID: 42586100. doi:10.1016/S1474-4422(26)00288-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。